The invention belongs to the technical field of biological
medicine and
cell therapy, and particularly relates to a preparation method of a human-derived nasal mucosa
mesenchymal stem cell medicine for treating
sepsis, which comprises the following steps:
cell separation: taking adult nasal mucosa tissues,
cutting into pieces, digesting with 0.25% pancreatin, and terminating
digestion with a DF12 culture medium containing 20% serum;
primary culture: after the tissue adheres to the wall for one week by using the first-step culture medium, replacing a DF12 culture medium containing 10% of serum, and after the cells
climb out of the tissue, centrifugally collecting the cells for
primary culture; 3,
primary culture: identifying a fourth generation of
cell surface marker in primary culture by
flow cytometry, the invention reveals the deep mechanism of function enhancement of HuNMSCs by inhibiting cell
autophagy, maintaining the integrity of a
cell membrane structure and improving the
survival rate of a
sepsis model through molecular means such as lipid metabonomics and the like for the first time, and the deep mechanism of function enhancement of the HuNMSCs is illustrated by using the HuNMSCs to inhibit cell
autophagy, maintain the integrity of a
cell membrane structure and improve the
survival rate of the
sepsis model. The possibility of treating sepsis by HuNMSCs is clarified, a brand new cell
treatment strategy is provided for sepsis, and a foundation is laid for subsequent clinical application.